EP0587065B1 — Programmed release tablets containing naproxen
Assigned to Alfa Wasserman SpA · Expires 1997-01-29 · 29y expired
What this patent protects
Programmed release tablets, to be administered by oral route, containing from 500 to 1,200 mg of naproxen, made by mixtures of an immediate release granulate dry compacted containing from 5% to 28% of naproxen, of a controlled release granulate dry compacted containing from 72% t…
USPTO Abstract
Programmed release tablets, to be administered by oral route, containing from 500 to 1,200 mg of naproxen, made by mixtures of an immediate release granulate dry compacted containing from 5% to 28% of naproxen, of a controlled release granulate dry compacted containing from 72% to 95% of naproxen and of a disintegrating agent. A portion of naproxen is released in a short time, so that the drug can quickly develop its therapeutic action reaching the necessary hematic levels, while the remaining portion is released in a longer interval of time, so as to allow the therapeutic coverage till the subsequent administration. The therapeutic coverage is effective for a period of 24 hours; thus the tablets object of the present invention are suitable for a once a day administration.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.